AstraZeneca today announced results from a phase II study evaluating the investigational drug vandetanib for the treatment of patients with locally advanced or metastatic papillary or follicular thyroid cancer. This study, ZACTHYF, showed that treatment with vandetanib significantly improved Progression Free Survival (PFS), the primary endpoint of the study, compared to placebo (Hazard Ratio=0.63, p=0.008). Median PFS was improved by 5 months (11.0 months for vandetanib and 5.8 months for placebo patients)...
More...
iHav.net - Your Uncensored Offtopic Community
If this is your first visit, please click the Sign Up now button to begin the process of creating your account so you can begin posting on our forums! The Sign Up process will only take up about a minute of two of your time.
|
|
|
Results 1 to 1 of 1
-
09-13-2010, 01:00 PM #1Senior Member
- Join Date
- Mar 2008
- Posts
- 12,518
- Downloads
- 0
- Uploads
- 0
Vandetanib Phase II Trial Shows Significant Improvement Of Progression Free Survival
Reply With QuoteSimilar Threads
-
Breast Cancer Survival Improves By Switching Drugs, Trial Shows
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 11-01-2011, 03:15 PM -
Phase 2 Trial Of Lexicon's LX1032, Telotristat Etiprate, Shows Positive Results In Ca
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 08-13-2011, 08:34 AM -
Obese Patients Treated With QNEXA Demonstrated Significant Improvement In Quality Of
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 08-06-2011, 09:35 AM -
Phase 2 Trial Of LX4211 Demonstrates Significant And Rapid Improvements In Multiple P
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 01-23-2010, 01:03 PM -
Phase 2 Trial Of LX4211 Demonstrates Significant And Rapid Improvements In Multiple P
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 01-23-2010, 01:01 PM
Bookmarks